Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis A/RES/73/3 vulnerable situations, and the need to develop integrated, people-centred, communitybased and gender-responsive health services based on human rights; 19. Commit to promoting access to affordable medicines, including generics, for scaling up access to affordable tuberculosis treatme nt, including the treatment of multidrug-resistant and extensively drug-resistant tuberculosis, reaffirming the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as amended, and also reaffirming the 2001 World Trade Organization Doha Declaration on the TRIPS Agreement and Public Health, which recognizes that intellectual property rights should be interpreted and implemented in a manner supportive of the right of Member States to protect public hea lth and, in particular, to promote access to medicines for all, and notes the need for appropriate incentives in the development of new health products; 20. Recall with concern that, until recently, no new medicines for tuberculosis treatment had been approved for over 40 years, and acknowledge that innovative approaches, including greater engagement between the public and private sectors, will be necessary to develop new vaccines, drugs and other health technologies to respond to the tuberculosis epidemic; 21. Recognize the lack of sufficient and sustainable financing for the tuberculosis response, including for the implementation of integrated, people -centred prevention, diagnosis, treatment and care of tuberculosis, including community-based health service delivery, and for tuberculosis research and innovation, including for the development and evaluation of better diagnostics, drugs, treatment regimens and vaccines, as well as other innovative care and prevention approaches, such as addressing social and economic factors of the disease; 22. Recognize that, to end the tuberculosis epidemic by 2030, reliable data on incidence, prevalence and mortality, where appropriate, disaggregated by income, sex, age and other characteristics relevant to national c ontexts, as well as the strengthening of national capacity for the use and analysis of such data, would be needed to ensure that collective knowledge is transformed into effective and timely action, and that progress at both the global and national levels needs to be reviewed regularly to ensure that we remain on target; 23. Take note with appreciation of the ongoing process of drafting a multisectoral accountability framework to accelerate progress to end tuberculosis, as agreed in World Health Assembly resolution 71.3 of 26 May 2018; 7 24. Commit to providing diagnosis and treatment with the aim of successfully treating 40 million people with tuberculosis from 2018 to 2022, including 3.5 million children, and 1.5 million people with drug-resistant tuberculosis, including 115,000 children, bearing in mind varying degrees of the burden of tuberculosis among countries, and recognize the constrained health system capacity of low -income countries, and thereby aiming to achieve effective universal access to qu ality diagnosis, treatment, care, and adherence support, without suffering financial hardship, with a special focus on reaching those who are vulnerable and the marginalized populations and communities among the 4 million people each year who have been most likely to miss out on quality care; 25. Commit to preventing tuberculosis for those most at risk of falling ill through the rapid scaling up of access to testing for tuberculosis infection, according to the domestic situation, and the provision of preventive treatment, with a focus on high-burden countries, so that at least 30 million people, including 4 million children under 5 years of age, 20 million other household contacts of people affected by __________________ 7 18-16895 See World Health Organization, document WHA71/2018/REC/1. 5/10